Anti-Yellow Fever Virus, NS1 (YFV-8007)

Leinco Technologies
Product Code: LEI-Y103
Product Group: Primary Antibodies
CodeSizePrice
LEI-Y103-250ug250 ug£434.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: Mouse IgG1
Antibody Clonality: Monoclonal
Antibody Clone: YFV-8007
Regulatory Status: RUO
Target Species: Yellow Fever Virus (YFV)
Application: Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
2 - 8°C Wet Ice
Storage:
This purified antibody is stable when stored at 2-8°C. Do not freeze.

Further Information

Concentration:
?1.0 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
Formulated in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
Formulated in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Long Description:
Yellow Fever Virus (YFV) is a single-stranded RNA virus belonging to the Flaviviridae family. It is transmitted to humans primarily through the bites of infected mosquitoes, particularly Aedes aegypti and Aedes albopictus. Yellow Fever has been a significant public health concern for centuries, causing periodic outbreaks and devastating epidemics in tropical regions of Africa and the Americas. The virus is responsible for a wide range of clinical manifestations, from asymptomatic or mild febrile illness to severe hemorrhagic fever and organ failure, which can be fatal. The disease is named for the jaundice that can occur in severe cases due to liver involvement. Yellow Fever vaccines have been highly effective in preventing the disease, and mass vaccination campaigns have played a crucial role in controlling outbreaks. However, Yellow Fever remains a global health threat, particularly in areas where vaccination coverage is low or lacking. Ongoing surveillance, mosquito control measures, and access to vaccination are essential components of the efforts to prevent and control Yellow Fever. NS1 (Non-Structural Protein 1) plays an important role in the viral life cycle and interacts with the host immune system aiding in immune evasion. NS1 has been investigated as a potential diagnostic marker for yellow fever infection, as it can be detected in patient samples.
Purity:
?90%
Target:
NS1

References

1. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector-Borne Diseases (DVBD). Link